Hovione
Hovione is a Contract Development and Manufacturing Organization with services for drug substance, drug product intermediate and drug product. The company has four FDA inspected sites in the United States, Portugal, Ireland and China development laboratories in Lisbon, Portugal and New Jersey, USA. Hovione is also present in the inhalation area, and provides a complete range of services, from active pharmaceutical ingredients, formulation development and devices. Hovione was the first Chemical/ Pharmaceutical Company to become a Certified B Corporation (certification), is a member of Rx-360 and EFCG.
History
Hovione was established in Portugal in 1959 by Ivan Villax with his wife, Diane Villax, and two other Hungarian refugees: Miklós [Horthy Jr.|Nicholas de Horthy] and Andrew Onody, the first two letters of the three founders’ names: HO, VI and ON were used to create the name Hovione.Hovione continues to be a privately held company with 5 plants - in Portugal, Macao, and New Jersey expanded in 2016, Taizhou in mainland China and Cork, Ireland - have a total reactor capacity of 1300 m³ and 1100 people worldwide. Since Hovione started operations in 1959, the company has patented more than 100 innovative chemical processes and produced industrially over 45 different APIs. All Hovione sites have been successfully inspected either by the FDA, the European Medicines Agency or the Pharmaceuticals and [Medical Devices Agency|PMDA] Japanese agency.
Hovione is a major source of semi-synthetic tetracyclines and corticosteroids, and is the largest independent supplier of contrast agents – these three families of compounds make up most of its generic product portfolio. The other half of the business focuses on exclusive projects including the development of innovator APIs and particle engineering.